Dear Healthcare Professional:

Title: Trobalt® 50mg, 100mg, 200mg, 300mg, 400mg tablets (retigabine) – Global Product Discontinuation

GlaxoSmithKline (GSK) is reminding Healthcare Providers that Trobalt® (retigabine) tablets (50mg, 100mg, 200mg, 300mg and 400mg) will no longer be available after June 2017. GSK intends to discontinue the product permanently. This is due to the very limited usage of the medicine and not for reasons of efficacy or safety. Please note in the United States the same medicine is called Potiga® (ezogabine), where it will also be discontinued to the same timelines and the where the healthcare provider actions below equally apply.

Therapeutic Indication:
Trobalt® is indicated as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalization in patients aged 18 years or older with epilepsy, where other appropriate combinations with other medicinal products have proved inadequate or have not been tolerated.

Action required by Healthcare Providers
• All patients must be withdrawn from Trobalt® by the end of June 2017. Healthcare providers are urged to safely transfer any remaining patients on Trobalt® to an alternative medication where required, at the discretion of the treating physician.
• Withdrawal of a patient from Trobalt® should be gradual and take place over a period of at least 3 weeks, in accordance with the prescribing information.
• From now on, healthcare providers should not begin treating any new patients with Trobalt®.
• Healthcare providers are requested to remind their colleagues of these actions, particularly if they are known to be a Trobalt® prescriber.

Action Being Taken by GlaxoSmithKline
GSK is working closely with our distributors to ensure the medicine remains available to existing patients until the end of June 2017. Any remaining Trobalt®/Potiga® stock will be recalled from pharmacies and wholesalers thereafter.